Brief: Veru Reports Muscle Data From 5 Clinical Studies Of Enobosarm

Veru

04/10/2023 13:48

Oct 4 (Reuters) - Veru Inc  VERU.O :
    * VERU REPORTS MUSCLE DATA FROM 5 CLINICAL STUDIES OF
ENOBOSARM
THAT SUPPORT THE ADVANCEMENT OF ENOBOSARM IN COMBINATION WITH
WEIGHT-LOSS GLP-1 DRUGS, OZEMPIC®, WEGOVY®, OR MOUNJARO®, TO
OPTIMIZE WEIGHT LOSS BY PREVENTING MUSCLE WASTING AND FURTHER
INCREASING FAT LOSS IN A PHASE 2B OBESITY CLINICAL STUDY
    * VERU INC - PHASE 2B CLINICAL OBESITY STUDY TO BE OPEN FOR
ENROLLMENT AS EARLY AS CALENDAR Q1 2024
    * VERU INC - PLANS TO CONDUCT A PHASE 2B DOUBLE-BLIND,
PLACEBO-CONTROLLED STUDY TO EVALUATE ENOBOSARM AND GLP-1 DRUG
COMBINATION

Source text for Eikon:  ID:nGNX5yVF8b 
Further company coverage:  VERU.O 

 ((Reuters.Briefs@thomsonreuters.com;))